Sector: MedicalTeva Pharmaceutical Industries (NASDAQ: TEVA)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 166 |
Technical : | 133 |
Performance : | 97 |
Overall: | 121 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 162 |
Technical : | 87 |
Performance : | 114 |
Overall: | 97 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 155 |
Technical : | 173 |
Performance : | 186 |
Overall: | 203 |
Number of Stocks: | 306 |
Headlines
- Rexahn Pharmaceuticals Provides Third Quarter 2009 Business Update
Nov 17, 2009 08:00 AM | TEVA
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
Nov 10, 2009 04:17 PM | TEVA
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
Nov 10, 2009 09:46 AM | TEVA
- Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE(R)-Related Patents
Nov 10, 2009 02:01 AM | MNTA, TEVA
- Antares Pharma Reports Third Quarter 2009 Financial and Operating Results
Nov 09, 2009 04:05 PM | AIS, TEVA
- Dr. Reddy's Laboratories (RDY) Impressive On Both Fundamental And Technical Basis
Nov 09, 2009 01:05 PM | AZN, BUCY, GSK, RDY, TEVA
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
Nov 04, 2009 06:52 AM | MRK, NVAX, NVS, TEVA
- Antares Pharma to Present at the Merriman Investor Summit 2009
Nov 03, 2009 04:05 PM | AIS, TEVA
- Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D(R) 12 Hour Tablets
Nov 03, 2009 03:35 PM | SNY, TEVA
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
Oct 29, 2009 06:52 AM | BIIB, GENZ, MBRX, TEVA
- Teva files amended complaint against Momenta and Sandoz
Nov 12, 2009 06:54 AM | MNTA, TEVA
- Lawyers target Israeli medical supplier
Oct 13, 2009 01:25 PM | TEVA
- Business Highlights
Aug 19, 2009 06:50 PM | BJ, DE, MRK, TEVA, WFC
- Teva Q2 Net Income Decreases
Jul 29, 2009 05:50 AM | TEVA
- Women underestimate menopause symptoms
Jul 15, 2009 06:42 PM | TEVA
- Teva and Antares Win FDA Approval for Needle-Free Device
Jun 30, 2009 12:56 PM | TEVA
- Teva Q1 Net Income Surges
May 06, 2009 04:00 AM | TEVA
- COPAXONE(R) Approved By Health Canada for Patients With Clinically Isolated Syndrome (CIS) Suggestive of Multiple Sclerosis (MS)
Apr 16, 2009 05:53 PM | TEVA
- Cubist Files Patent Infringement Lawsuit Against Teva Parenteral Medicines
Mar 24, 2009 01:02 PM | CBST, TEVA
- BRIEF: Bedford Employer Named Israel's Strongest Company
Jan 15, 2009 01:21 PM | DNB, TEVA
- Teva Receives Final Approval for Generic Prevacid® Delayed-Release Capsules
Nov 10, 2009 04:52 PM | TEVA
- Teva Receives Favorable Court Decision Regarding Generic Prevacid® SoluTab
Nov 10, 2009 09:51 AM | TEVA
- Market Watch: Sunwin International Neutraceuticals - November 10, 2009
Nov 10, 2009 09:51 AM | BAC, MRK, SUWN, TEVA
- Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE®-Related Patents
Nov 10, 2009 03:53 AM | MNTA, TEVA
- Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets
Nov 03, 2009 03:54 PM | TEVA
- Teva Reports Third Quarter 2009 Results
Nov 03, 2009 01:52 AM | TEVA
- MichBio Expo &Amp; Conference Exhibitors Profiled
Oct 27, 2009 11:53 AM | ENL, PFE, TEVA
- Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit Against Generic Filer for Patent Infringement
Oct 16, 2009 05:52 PM | MNTA, MYL, TEVA
- Teva Provides Update on Generic Seroquel® Litigation
Sep 25, 2009 04:51 PM | AZN, TEVA
- Teva Provides Update on Generic Evista® Litigation
Sep 24, 2009 06:54 AM | LLY, TEVA
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
TEVA
|
Compare to S&P
|
| YTD |
22.81 %
|
1.44 %
|
| 4 Weeks |
3.94 %
|
3.39 %
|
| 12 Weeks |
1.44 %
|
-4.81 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 7.23 %
|
|
EPS Growth in Last Year: 23.61 %
|
|
Sales Growth in Last Quarter: 4.41 %
|
|
Sales Growth in Last Quarter: 24.91 %
|
|
